Entresto Drug Analysis Report 2017-2026 - ResearchAndMarkets.com

DUBLIN--()--The "Drug analysis: Entresto" drug pipelines has been added to ResearchAndMarkets.com's offering.

Entresto is a first-in-class angiotensin receptor/neprilysin inhibitor consisting of valsartan and sacubitril. Valsartan is an angiotensin receptor blocker (ARB) that competes with angiotensin II for binding to the AT1 receptor, while sacubitril is a prodrug that inhibits neprilysin, an enzyme responsible for the breakdown of several vasoactive peptides. The combined action of both molecules attenuates vasoconstriction and sodium retention, helping to improve the underlying pathology of chronic heart failure.

List of Figures

Figure 1: Entresto for chronic heart failure - SWOT analysis

Figure 2: Drug assessment summary of Entresto for chronic heart failure

Figure 3: Drug assessment summary of Entresto for chronic heart failure

Figure 4: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: Entresto drug profile

Table 2: Entresto Phase III data in chronic heart failure

Table 3: Ongoing pivotal trials for Entresto in chronic heart failure

Table 4: Entresto sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/76kwb3/entresto_drug?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiovascular Drugs